Use of Bisphosphonates in Prostate Cancer: Current Status

Overview

Journal Indian J Urol

Specialty Urology

Date 2009 Aug 14

PMID 19675763

Authors

Rishi Nayyar

Narmada P Gupta

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates are a relatively newer class of drugs which have been used for the prevention of skeletal related complications of age related osteoporosis or metastatic disease from carcinoma breast or multiple myeloma. Their role in the management of prostate cancer is still under evolution. We hereby review the ongoing and some published randomized trials to define the role of bisphosphonates in various stages of prostate cancer.

References

Smith M, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003; 169(6):2008-12. DOI: 10.1097/01.ju.0000063820.94994.95. View

Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A . Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2004; 94(4):524-7. DOI: 10.1111/j.1464-4096.2004.04919.x. View

Diamond T, Higano C, Smith M, Guise T, Singer F . Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004; 100(5):892-9. DOI: 10.1002/cncr.20056. View

Jagdev S, Coleman R, Shipman C, Croucher P . The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84(8):1126-34. PMC: 2363858. DOI: 10.1054/bjoc.2001.1727. View

Green J . Bisphosphonates in cancer therapy. Curr Opin Oncol. 2002; 14(6):609-15. DOI: 10.1097/00001622-200211000-00004. View

Oefelein M, Ricchiuti V, Conrad W, Resnick M . Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002; 168(3):1005-7. DOI: 10.1016/S0022-5347(05)64561-2. View

Magnetto S, Boissier S, Delmas P, Clezardin P . Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999; 83(2):263-9. DOI: 10.1002/(sici)1097-0215(19991008)83:2<263::aid-ijc19>3.0.co;2-t. View

Ross J, Saunders Y, Edmonds P, Patel S, Broadley K, Johnston S . Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003; 327(7413):469. PMC: 188427. DOI: 10.1136/bmj.327.7413.469. View

Stock H, Schneider A, Strauss E . Osteoporosis: a disease in men. Clin Orthop Relat Res. 2004; (425):143-51. View

10.

Smith M, McGovern F, Fallon M, Schoenfeld D, Kantoff P, Finkelstein J . Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001; 91(12):2238-45. View

11.

Dearnaley D, Sydes M, Mason M, Stott M, Powell C, Robinson A . A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003; 95(17):1300-11. DOI: 10.1093/jnci/djg038. View

12.

Ockrim J, Lalani E, Laniado M, Carter S, Abel P . Transdermal estradiol therapy for advanced prostate cancer--forward to the past?. J Urol. 2003; 169(5):1735-7. DOI: 10.1097/01.ju.0000061024.75334.40. View

13.

Oefelein M, Resnick M . The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am. 2004; 31(2):313-9. DOI: 10.1016/j.ucl.2004.02.002. View

14.

Morabito N, Gaudio A, Lasco A, Catalano A, Atteritano M, Trifiletti A . Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2004; 19(11):1766-70. DOI: 10.1359/JBMR.040813. View

15.

Siddiqui N, Shetty K, Duthie Jr E . Osteoporosis in older men: discovering when and how to treat it. Geriatrics. 1999; 54(9):20-2, 27-8, 30 passim. View

16.

Townsend M, Sanders W, NORTHWAY R, Graham Jr S . Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997; 79(3):545-50. DOI: 10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3. View

17.

Parker C . The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005; 95(7):935-8. DOI: 10.1111/j.1464-410X.2005.05441.x. View

18.

Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

19.

Gilbert S, McKiernan J . The role of bisphosphonates in preventing skeletal complications of hormonal therapy. Urol Clin North Am. 2006; 33(2):191-9, vi. DOI: 10.1016/j.ucl.2005.12.009. View

20.

Russell R, Croucher P, Rogers M . Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999; 9 Suppl 2:S66-80. DOI: 10.1007/pl00004164. View